Study details
Enrolling now
Promoting HIV Risk Reduction Among People Who Inject Drugs
Yale University
NCT IDNCT04738825ClinicalTrials.gov data as of Apr 2026
Target enrollment
526
Study length
about 4.7 years
Ages
18+
Locations
6 sites in CT, MA
About this study
This trial is testing a new approach called CoMPASS to help people who inject drugs reduce their risk of getting HIV. CoMPASS uses contingency management, which provides rewards for good behavior, along with support services and PrEP adherence. The goal is to see if this method helps prevent HIV infection.
Based on ClinicalTrials.gov records.
What participants do
- 1.Participate in Contingency Management with stepped care to PrEP adherence and support services (CoMPASS)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Psychiatry / Mental Health, Infectious